

Références

- 1 www.nobelprize.org/nobel_prizes/medicine/laureates/2008/hausen-facts.html (page consultée pour la dernière fois le 5 février 2016).
- 2 www.nicer.org (page consultée pour la dernière fois le 5 février 2016).
- 3 Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. *Epidemiol Infect.* 2016;144:449–68.
- 4 Comité consultatif mondial sur la sécurité des vaccins: Déclaration du GACVS sur l'innocuité des vaccins contre le papillomavirus humain (PVH) – 17 décembre 2015.
- 5 www.swissmedicinfo.ch (page consultée pour la dernière fois le 5 février 2016).
- 6 Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. *JAMA* 2009;302:750–7.
- 7 Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K, Fink K, Hviid A. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. *JAMA.* 2015;313:54–61.
- 8 Alperovitch A, Elbaz A, Faye A, Fournier A, Galanaud P, Heard I, Bader-Meunier B, Mrejen S. ANSM/CNAMTS – Vaccin anti-HPV et risque de maladies auto-immunes: étude pharmacoépidémiologique. Rapport final, septembre 2015. http://ansm.sante.fr/content/download/80841/1023043/version/1/file/Ansm_Gardasil-Hpv2_Rapport_Septembre-2015.pdf
- 9 Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, Sy LS, Chao C, Hechter R, Tseng HF. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. *JAMA Neurol.* 2014;71:1506–13.
- 10 Ojha RP, Jackson BE, Tota JE, Offutt-Powell TN, Singh KP, Bae S. Guillain-Barré syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. *Hum Vaccin Immunother.* 2014;10:232–7.
- 11 Baxter R, Bakshi N, Fireman B, Lewis E, Ray P, Vellozzi C, Klein NP. Lack of association of Guillain-Barré syndrome with vaccinations. *Clin Infect Dis.* 2013;57:197–204.
- 12 Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, Emery M, Liaw KL, Jacobsen SJ. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. *J Intern Med.* 2012;271:193–203.
- 13 Huygen F, Verschuere K, McCabe C, Stegmann JU, Zima J, Mahaux O, Van Holle L, Angelo MG. Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data. *EBioMedicine.* 2015 Jul 6;2(9):1114–21.
- 14 European Medicines Agency. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500196773.pdf (page consultée pour la dernière fois le 5 février 2016).
- 15 Brinthe LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. *Vaccine.* 2015;33:2602–5.
- 16 Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. *Vaccine.* 2013;31:4961–7.